01707nas a2200277   4500000000100000008004100001653001200042653002300054653001900077653002300096653002700119653001100146100002100157700001400178700001800192700001600210700001500226700001700241700001500258245007800273856007200351300001000423490000700433520097500440022001401415       2015                            d10aleprosy10aKidney dysfunction10aHansen disease10aGlomerulonephritis10aChronic kidney disease10aBrazil1 aSilva Júnior GB1 aDaher EDF1 aPires Neto RJ1 aPereira EDB1 aMeneses GC1 aAraújo SMHA1 aBarros EJG00aLeprosy Nephropathy : A Review of Clinical and Histopathological Features  uhttp://www.scielo.br/pdf/rimtsp/v57n1/0036-4665-rimtsp-57-01-15.pdf  a15-200 v573 a<p>Leprosy is a chronic disease caused by Mycobacterium leprae, highly incapacitating, and with systemic involvement in some cases. Renal involvement has been reported in all forms of the disease, and it is more frequent in multibacillary forms. The clinical presentation is variable and is determined by the host immunologic system reaction to the bacilli. During the course of the disease there are the so called reactional states, in which the immune system reacts against the bacilli, exacerbating the clinical manifestations. Different renal lesions have been described in leprosy, including acute and chronic glomerulonephritis, interstitial nephritis, secondary amyloidosis and pyelonephritis. The exact mechanism that leads to glomerulonephritis in leprosy is not completely understood. Leprosy treatment includes rifampicin, dapsone and clofazimine. Prednisone and non-steroidal anti-inflammatory drugs may be used to control acute immunological episodes.</p>
  a1678-9946